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Abstract
Juvenile Idiopathic Arthritis (JIA) is a group of chronic heterogenous disorders that manifests as joint inflammation
in patients aged <16 years. Globally, approximately 3 million children and young adults are suffering from JIA with
prevalence rates consistently higher in girls. The region of Africa and Middle East constitute a diverse group of
ethnicities, socioeconomic conditions, and climates which influence the prevalence of JIA. There are only a few
studies published on epidemiology of JIA in the region. There is an evident paucity of adequate and latest data
from the region. This review summarizes the available data on the prevalence of JIA and its subtypes in Africa and
Middle East and discusses unmet needs for patients in this region. A total of 8 journal publications were identified
concerning epidemiology and 42 articles describing JIA subtypes from Africa and Middle East were included. The
prevalence of JIA in Africa and Middle East was observed to be towards the lower range of the global estimate. We
observed that the most prevalent subtype in the region was oligoarticular arthritis. The incidence of uveitis and
anti-nuclear antibody (ANA) positivity were found to be lower as compared to the incidence from other regions.
There is a huge unmet medical need in the region for reliable epidemiological data, disease awareness, having
regional and local treatment guidelines and timely diagnosis. Paucity of the pediatric rheumatologists and
economic disparities also contribute to the challenges regarding the management of JIA.
Background
Juvenile Idiopathic Arthritis (JIA) is the most common
chronic heterogenous rheumatological disorder that
manifests in patients aged less than 16 years and, in
some cases, can cause severe impairment and disability.
It constitutes various subtypes with different clinical
manifestations, genetic markers, and pathogenesis [1].
According to the most commonly used classification
proposed by the International League of Associations for
Rheumatology (ILAR), seven different subtypes are rec-
ognized to classify patients: oligoarticular, rheumatoid
factor (RF) positive polyarticular, RF negative polyarticu-
lar, enthesitis related arthritis (ERA), systemic onset,
psoriatic arthritis, and undifferentiated arthritis [1, 2].
The precise cause and pathogenesis of JIA are un-
known; however, genetic, environmental, and auto-
immune factors are hypothesized to play a role in the
development of JIA [3, 4]. Socioeconomic status is asso-
ciated with delayed access to rheumatology care and
worsening disease severity in JIA patients, directly affect-
ing their well-being and quality of life [5].
Globally, approximately 3 million children and young
adults are estimated to suffer from JIA [6, 7]. The global
prevalence of JIA has been estimated to range from 3.8
to 400/100,000 with an incidence of 1.6 to 23/100,000
[8]. Girls were consistently found to be at a higher risk
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than boys, and oligoarticular subtype was found to be
predominant [8].
Africa and Middle East countries constitute a diverse group
of ethnicities, socioeconomic backgrounds, and climatic con-
ditions. Few studies have assessed the prevalence of JIA in the
region and there is a paucity of adequate and latest data from
the region on the epidemiology of JIA. A comprehensive un-
derstanding of JIA in the regions is required.
Given the social, economic, and cultural diversity of
African and Middle Eastern countries, many studies
conducted in this region may underestimate the
prevalence of JIA. The aim of this review article was
to critically assess and summarize the available pub-
lished data on epidemiology and demographics of JIA
in the Africa and Middle East region and highlight
the unmet needs of the region and current efforts be-
ing undertaken in the region to generate quality data
on JIA and the way forward to address the lacunae.
The unmet needs section describes unique challenges
from the region by the authors from independent
references.
Methods
Our methodology for searching the NCBI PubMed data-
base included the following search strings: “((juvenile
idiopathic arthritis) OR JIA) AND (Africa OR (Middle
East) OR AfME) AND prevalence.” Search terms also in-
cluded “Juvenile Chronic Arthritis” and “Juvenile
Rheumatoid Arthritis.” Additional searches were con-
ducted to include “(Africa OR (Middle East) OR AfME)”
with individual countries in the region.
Publications were included if they evaluated JIA dis-
ease prevalence in the individual African or Middle East-
ern countries or in African and Middle Eastern regions,
using prospective or retrospective study designs or a sys-
tematic review or meta-analysis approach between May
1988 to April 2021. We included both population based
and hospital-based studies. Prevalence rates were ex-
tracted from the articles and were not estimated.
For demographic section, publications were included if
they evaluated JIA disease subtype and characteristics in
individual African of Middle eastern countries or region
between May 1988 to April 2021.
From the articles summarizing epidemiology data from
the region, parameters extracted were region/country,
prevalence, incidence, sample size, number of cases, clas-
sification criteria, age range, study period, and study de-
sign (population and setting) were included in (Table 1).
From the articles summarizing demographic data from
the region, parameters such as country, number of cases,
female to male ratio, mean age of onset (years), distribu-
tion of subtypes, presence, definition and methodology
of testing for antinuclear antibody (ANA) positivity, uve-
itis, Rheumatoid factor (RF) positivity, and human
leukocyte antigen HLA-B27 were extracted and included
in (Table 2).
Additionally, online databases of the American College
of Rheumatology, the Asia-Pacific League of Associa-
tions for Rheumatology and the European League
Against Rheumatism, Arab League of Associations of
Rheumatologists, African league of Associations of
Rheumatologists, and South African Rheumatism and
Arthritis Association were searched for abstracts pre-
sented at annual congresses.
Publications in languages other than English, evaluat-
ing JIA incidence alone, or characterizing one subtype of
JIA and or that were published prior to 1988 were ex-
cluded. Case reports and case series, editorials, letters to
the editor and duplicates were also excluded. For the
demographics search genetic matched case controls
studies and studies discussing one single subtype of JIA
were also excluded to limit selection bias. Please refer to
Fig. 1.
Assessment of the risk of bias each study included in
our prevalence search was assessed using the Hoy 2012
[9] tool to address of internal and external validity
(Table 3). Each parameter was assessed as either low or
high risk of bias. Overall assessment of bias was accord-
ing to number of “high” risk of bias in the parameters
per study: low ≤2, moderate [3, 4], and high ≥5.
All articles included in our search were assessed for
their quality in terms of methodology, sample size, study
design, classification criteria, study period, characteristics
and limitations summarized in (Table 4) and (Table 5)
to address wide heterogenicity of design of the study
types included and limit potential bias with assessment
of the results.
Search results: epidemiology of JIA in Africa and Middle
East
Our PubMed search on epidemiology identified a total
of 8 journal publications for all JIA subtypes. The results
included 1 systematic review and meta-analysis con-
ducted in Africa between 1975 up to 2014 [10] and
seven publications from individual countries [11–17].
One article was excluded from our search as it included
only one confirmed JIA case [18].
Discussion: epidemiology
The prevalence of JIA in Africa and Middle east was
noted to be towards the lower range of the global esti-
mate, estimated as (3.8 to 400 per 100,000) [8]. We iden-
tified the lowest prevalence in Africa with prevalence
rate of less than 3.43 per 100,000, [12, 16] and less than
22 per 100,000 in the Gulf, [11, 13, 14] and highest
prevalence identified in Turkey i.e., 64 per 100,000 [15].
Our search identified two studies from Kuwait, [13,
14] that used American College of Rheumatology (ACR)
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criteria of classification [13, 14] in hospital-based surveys
and included patients aged <12 years. The ACR 1978 de-
fined Juvenile Rheumatoid Arthritis (JRA) as persistent
arthritis in one or more joints for at least 3 months with
exclusion of diseases with similar manifestations. The
arthritis was considered polyarticular if five or more
joints are involved within 6 months of the onset [19].
The 1988 study extended over a 10-year period (1978-
1987) and estimated a prevalence rate of 22 per 100,000
[13]. The other study estimated a prevalence of 18.7 per
100,000 (15.3-22.6) and an incidence of 2.8 (2.3-3.4) per
100,000 [95% CI] [14].
One community based epidemiological study from
Turkey, screened 46,813 children from 5 different geo-
graphical regions, and reported a prevalence of 64 per
100,000 (43-91 [95% CI]) for juvenile chronic arthritis
(including spondylarthritis or psoriatic arthritis) [15].
The EULAR criteria was used which defined Juvenile
Chronic Arthritis as the chronic arthritis marked by
swelling or effusion, or presence of 2 or more of the fol-
lowing: limitation of range of motion, tenderness or pain
on motion, and increased heat in one or more joints for
at least 6 weeks and included similar onset types such as
juvenile Ankylosing Spondylitis and juvenile Psoriatic
Arthritis [20].
Abdwani et al, 2015 conducted a multi-center, medical
chart review in Oman between 2004 to 2013, using ILAR
2004 criteria in patients aged <13 years. The prevalence
was estimated to be 20 per 100,000 and incidence was
reported to be 2 per 100,000 [11].
One Egyptian study screened children <15 years of age
in a population based epidemiological study in Sharkia
Governate (2009-2010), using the 2004 revised ILAR
classification. The prevalence was reported to be 3.43
per 100,000 (3.1–4.3) [95% CI] with overall mean age at
diagnosis being 10.5 ± 3.6 (range 4–15) years. There was
a statistically noticeable difference between urban and
rural populations [12]. Another Egyptian community-
based study used The European League Against
Rheumatism (EULAR) criteria to confirm and classify
cases of Juvenile Chronic Arthritis (JCA) in children
aged 10-15 years old. A prevalence rate of 3.3 per
100,000 cases [4–62] [95% CI] was reported [10, 17].
Drawing conclusions on the prevalence of JIA in Af-
rica and Middle East should be approached with caution
for several reasons. First, due to the limited number of
Table 1 Epidemiology of Juvenile Idiopathic Arthritis in Africa and Middle East
Sr.
No.



















2 Khuffash et al., 1988
[13]
Kuwait 22/100,000(NA) NA 41 186,363 ACR (for 3 months) 0-11 1978-
1987






108 JCA 577,540 ACR (for 3 months) 0-11 1981-
1988









5 Ozen et al., 1998 [15] Turkey 64/100,000 (43-
91)
NA 30 JCA 46,813 EULAR (for 6
weeks)
0-15 1997













et al., 2013 [16]
Cameroon 1/100,000 (0.7-1.3) NA 35 34,782 Not reported NA 2004-
2012
8 Tayel et al., 1999 [17] Egypt Alexandria 3.3/100,000 (4-62) NA NA 1500 EULAR 10-
15years
NA
ACR, American College of Rheumatology Association; EULAR, The European League Against Rheumatism; ILAR, International League of Associations for
Rheumatology; JCA, juvenile chronic arthritis; JIA, juvenile idiopathic arthritis; NA, not applicable.
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updated prospective epidemiological studies conducted
in the region, and second to the wide heterogeneity
of different study designs, case ascertainment and
variable study qualities that assessed JIA prevalence in
the region.
A wide variance of the prevalence rates was also ob-
served. This variance can be explained by the wide diver-
sity of the healthcare systems capabilities across the
region, genetic, disease awareness, smaller sample size,
and diagnostic challenges that are more prominent in
some countries than others. The variance can also be at-
tributed to absence of electronic healthcare system in
some countries, difference in methodologies of case as-
certainment, and lack of data collection through regis-
tries enough to publish findings. The authors provided
Table 4 to outline the quality assessment of articles in-
cluded from the search and Table 3 to assess the risk of
bias for each study included from the search
Our search identified studies with different study de-
signs. Community-based surveys were used in Turkey [15]
and Egypt [12] while hospital-based chart reviews were
utilized in Oman, Kuwait and Cameroon [11, 13, 14, 16].
Community based prevalence studies are known to pro-
vide higher prevalence rates compared to hospital-based
studies and allow for undiagnosed cases to be included [8,
21]. Five of the seven local country studies were multi-
centered [11, 12, 14–16], and two studies didn’t report de-
tails [13, 17]. Only one study conducted in Turkey used
diagnostic and clinical examinations to confirm cases [15].
Ideally, studies estimating prevalence should use stan-
dardized methods and diagnostic criteria [21] for ascer-
taining the subtypes from the community and include
well trained clinicians experienced in the field of rheuma-
tology to confirm diagnosis. Three of the included studies
were conducted more than 24 years ago where study
methods, JIA disease and study reporting guidelines have
drastically changed and developed. Recent studies tend to
better describe the methodology and the results clearly
due to evolution of reporting guidelines which was not the
case with older studies [21].
JIA nomenclature has changed over the years from
JRA to JCA to most recently adopting JIA (Juvenile Idio-
pathic Arthritis). Over the years, different JIA subtype
classifications have been proposed and revisions have
been implemented. Hence, the data found with use of a
certain classification may reflect changes due to time ra-
ther than a real difference because of the classification
itself [21, 22].
The variation in results may be attributed to the differ-
ent classifications (ACR, [13, 14] ILAR, [11, 12] and
EULAR [15, 17] used and, in some cases not defining
the exact classification used [16].
Variability in disease presentation among the subtypes
of JIA may make it difficult to compare prevalence esti-
mates for this condition across different study settings.
And like other inflammatory arthritis diseases, extended
remissions occur, so that prevalence estimates may in-
clude individuals who are experiencing symptoms while
Fig. 1
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Table 4 Characteristics of Studies - Epidemiology
Sr.
No.
























•The studies included do not
follow a standardized diagnostic
criterion
•Risk of bias assessed for each
study included
•Studies on JIA were not pooled

































undiagnosed cases in the
community and nonreferral by
primary care practitioners
•Children aged between 12 and
16 years were excluded.
•Female children possibly
underrepresented













children <13 years of age were
included
•Potential referral bias, study









































numbers due to undiagnosed
cases in the community and
























NA 1500 NA EULAR NA •Cross sectional
•School based
•The prevalence period, method
of data collection studied is
unclear
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Table 5 Quality Assessment of Articles Selected – Demographics Results
Sr.
No.

















•There was disproportionate number
of patients included from various
geographical areas
•Potential underrepresentation of
milder forms of JIA and referral bias
•Wide variation in tests and
evaluation can affect evaluations or
tests
•Some countries could not be
included
•Method of grouping some countries
in a particular geographical area was
arbitrary
•Wide variation in healthcare
resources across countries













•It was a cross-sectional analysis
•There is a possibility of patients
•selection bias as the participating
centers did not enroll the same
number of patients
•Wide variation in healthcare
resources across countries
Country






•Potential referral bias of more severe
cases specifically systemic JIA









undiagnosed cases in the
community and nonreferral by
primary care practitioners




•No current data is available








children <13 years of age were
included
•Potential referral bias, study might
have missed on milder cases




30 EULAR 1997 •Community-based study from 5
districts in turkey
•Possible Exclusion of undiagnosed
cases not identifiable from
questionnaires may have led to
possible underestimation
7 Abou El-Soud et al., 2013
[12]







•First population-based study from
Sharkia governate
•Large population cohort included 19
districts
•Possible underestimation of
numbers due to undiagnosed cases
in the community and nonreferral
from primary care practitioners






•Possible referral bias and
underestimation of milder forms of
disease
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Table 5 Quality Assessment of Articles Selected – Demographics Results (Continued)
Sr.
No.











•The objective of the study was to
cross-culturally adapt and validate
child/adult version of the Juvenile
Arthritis Multidimensional
Assessment
Report (JAMAR) in JIA patients
•Possible selection bias
•Only selected centers were invited
to participate




•Potential referral bias could have
caused the overall frequency of
familial JIA and recurrence risk
•Heterogeneous patients were
included and were not compared
with controls




•The objective of the study was to
cross-culturally adapt and validate
child/adult version of the Juvenile
Arthritis Multidimensional
Assessment
Report (JAMAR) in JIA patients
Possible selection bias
•Only selected centers were invited
to participate




•Single center tertiary hospital study
•Higher frequency of oligoarticular
JRA, polyarticular and systemic onset
JRA could be due to referral bias to
tertiary care facilities




•The objective of the study was to
cross-culturally adapt and validate
child/adult version of the Juvenile
Arthritis Multidimensional
Assessment
Report (JAMAR) in JIA patients
•Possible selection bias
•Only selected centers were invited
to participate




•The objective of the study was to
cross-culturally adapt and validate
child/adult version of the Juvenile
Arthritis Multidimensional
Assessment
Report (JAMAR) in JIA patients
•Possible selection bias
•Only selected centers were invited
to participate




•The objective of the study was to
cross-culturally adapt and validate
child/adult version of the Juvenile
Arthritis Multidimensional
Assessment
Report (JAMAR) in JIA patients
•Possible selection bias
•Only selected centers were invited
to participate




•The objective of the study was to
cross-culturally adapt and validate
child/adult version of the Juvenile
Arthritis Multidimensional
Assessment
Report (JAMAR) in JIA patients
•Possible selection bias
•Only selected centers were invited
to participate




•Single center tertiary hospital study
•Center covers patients from all over
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Table 5 Quality Assessment of Articles Selected – Demographics Results (Continued)
Sr.
No.







Kenya, greater East and Central
African region
•RF positive polyarthritis patients may
be overrepresented which were
classified using only one positive
assay
•Possible underrepresentation of RF
negative polyarthritis
•Potential referral bias of severe forms
of the disease




•The objective of the study was to
cross-culturally adapt and validate
child/adult version of the Juvenile
Arthritis Multidimensional
Assessment
Report (JAMAR) in JIA patients
•Possible selection bias
•Only selected centers were invited
to participate





•The collected data may be
incomplete and incorrect due to the
retrospective study design
•HLA-B27 test was not done for all
patients
20 Shafaie et al., 2018 [59] Iran Cross sectional
survey parent/PRO
102 ILAR 2012 •The objective of the study was to
cross-culturally adapt and validate
child/adult version of the Juvenile
Arthritis Multidimensional
Assessment
Report (JAMAR) in JIA patients
•Possible selection bias
•Only selected centers were invited
to participate






•The study included lower number of
patients as compared to other
studies conducted in the country





•The study included lower number of
patients
•Short follow-up time
23 Kasapçopur et al., 2004 [51] Turkey Retrospective
hospital chart review
198 ILAR NA •Single center study
•Study conducted to determine
frequency of ANA positivity and
uveitis in newly diagnosed JIA
patients





•Potential referral bias of milder forms
of comorbidities such as uveitis








•Included patients aged 7-17 years di-
agnosed to ILAR criteria
•Study aimed to investigate JIA
patients school absenteeism and
school functioning
•Potential selection and referral bias
•Cross-sectional study design limits
the ability to determine temporal
relationships between risk factors
and both of school absenteeism and
of poor school functioning






•Included patients aged 8-18 years di-
agnosed to ILAR criteria
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Table 5 Quality Assessment of Articles Selected – Demographics Results (Continued)
Sr.
No.







questionnaire •Small study sample
•Study aimed to identify
determinants of impaired HRQOL in
children with JIA
•Cross-sectional design limits the
ability to determine temporal
relationships between risk factors
and HRQOL
27 Albokhari et al., 2019 [36] Saudi Arabia cross sectional health
related quality of life
survey
44 ILAR 2017 •Single center study
•Study aimed to evaluate effect of JIA
on HRQOL
•Single center study
•Potential referral bias and over
representation of more severe forms







•Diagnosis was confirmed by
pediatric rheumatologist





•The aim of the study was to assess
HRQoL- related impact of JIA
•Demographics, subtype, clinical and
lab parameters were obtained for
patients
•Potential selection and referral bias
over-representation of severe forms







•18 months follow up
•Potential referral bias and under
representation of milder forms
31 Bouaddi et al., 2013 [40] Morocco Cross-sectional
prospective
33 ILAR 2013 •Aim of the study was to assess the













•Two different classifications were
used for each study period
•1994-1998 EULAR
•2006-2010 ILAR
•ANA test was not routinely available








34 Olaosebikan et al., 2017 [54] Nigeria Retrospective
hospital chart review
28 not specified 2010-
2016
•Single center
•Patients referred to adults
rheumatologists due to lack of
pediatric rheumatology service
•The study included all types of
pediatric rheumatology patients,
hence unreliable representation of
JIA demographics











48 ILAR 2018 •Aim of the study was to assess
functional disability in JIA patients
•Single-centered
•Potential referral bias and
underrepresentation of milder forms






Al-Mayouf et al. Pediatric Rheumatology          (2021) 19:166 Page 22 of 30
cases that are in remission may be missed. Less severe
subtypes and symptoms like oligoarticular are not fur-
ther referred for diagnosis by a specialist pediatric
rheumatologist. Most of the country specific prevalence
studies set the upper age limit of 12 and 15 years for in-
clusion [11–14, 17] which can lead to underreporting of
patients with onset of symptoms during adolescents be-
tween 12-16 years of age [21].
A lack of adequate number of rheumatologists and
pediatric rheumatologists further adds to the challenge
of accurately estimating the incidence and prevalence of
rheumatological diseases [23]. This may contribute to
the skewness of the results toward higher prevalence in
urban areas.
There are too few pediatricians across the Africa and
Middle East region to adequately cater to the JIA popu-
lation in the region, also an appropriate referral hier-
archy would be required to address the gap [24]. Paucity
of well-trained pediatric rheumatologists, specifically in
the rural areas compel many patients to visit other trad-
itional healers [25] or healthcare professionals like gen-
eral practitioners, family physicians [24] or orthopedics
rather than rheumatologists.
Awareness of JIA is increasing and is reflected in the
increasing prevalence across the globe and the region
[26]. As healthcare systems and economies are develop-
ing, more resources are allocated towards improving
diagnosis and management of childhood illnesses. No-
ticeably, most data in the literature describes evidence
from the Middle East and North Africa region. There
are far fewer data available on prevalence from the sub-
Saharan Africa region. The absence of data, however,
does not imply absence of the disease.
Robust epidemiological data is needed from the region
to assess the impact of JIA on children from Africa and
the Middle East through the development of prospective
community based epidemiological studies covering re-
gions rather than individual country-based studies
needed to accurately determine the prevalence of JIA
across the region. In addition, the development of na-
tional and regional registries can further facilitate the
generation of evidence on JIA prevalence from this re-
gion [9].
Other solutions include increased capacity of general
health care practitioners and pediatric rheumatologists
to address healthcare access for patients underdiagnosed
or undertreated. In addition, raise awareness to general
and specialized practitioners on MSK examination skills
and define uniform case ascertainment or referral cri-
teria [27].
Search Results: Demographics
Our literature search identified 42 articles describing JIA
subtypes and demographics from Africa and Middle
East. We identified one global study that included 1209
patients from Africa and Middle East, [22] and one mul-
ticenter regional study from seven Arab countries, [28]
and 40 publications of data from individual countries
[11–15, 29–63]. A summary of the demographics is pre-
sented in Table 2.
Table 5 Quality Assessment of Articles Selected – Demographics Results (Continued)
Sr.
No.












•Aim of the study was to assess
access to care for JIA patients










•Patients above 14 years of age were
not included






•Registry is not representative of all
centers from Turkey







•1-year study duration, some patients










•Referral bias may explain low
prevalence of oligoarticular JIA and
low uveitis
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Discussion: Demographics
The findings of this review support that the most preva-
lent subtype in Africa and Middle East is oligoarticular
JIA subtype, followed by polyarticular RF negative, and
systemic subtype. Our findings support the global epi-
demiology, treatment, and outcome of childhood arth-
ritis throughout the world (EPOCA) study findings [22]
and the regional Pediatric Rheumatology Arab Group
(PRAG) study [28].
Oligoarticular subtype was observed to be the most
frequent subtype based on the 15 local studies [12, 15,
29–31, 37, 38, 43, 44, 49, 50, 57, 59, 62, 63]. Followed by
polyarticular then systemic JIA.
On a regional scale, the EPOCA study, enrolled
1209 JIA patients using ILAR 2004 criteria, from 15
participating countries from Africa and Middle East
region. The study identified oligoarticular JIA (37.8%),
RF-negative polyarthritis (22.4%) and systemic JIA
(16.9%) as the predominant subtypes in Africa and
the Middle East. A predominance of the female gen-
der (61.6%) was observed with mean age of onset of
6.0 (2.9-9.8) and 5.9% of cases had positive signs of
uveitis with predominance of uveitis amongst oligoar-
ticular sub-type in 12.4% of the cases from the region
[22].
In the PRAG study, 702 JIA patients with a disease
duration of more than one year and fulfilled the ILAR
criteria were enrolled from 14 pediatric rheumatology
centers across seven Arab countries. Oligoarticular JIA
(34.9%) was identified as the predominant subtype. Poly-
articular JIA (29.5%) and systemic JIA (24.5%) were the
second and third most identified subtypes [28].
Oligoarticular subtype has also been the most com-
mon across all regions in Europe and North and Latin
America except Southeast Asia [8, 22, 64, 65]. A similar
finding has also been observed from a JIA
epidemiological study conducted in Canada that focused
on ethnicity as a risk factor in JIA phenotypes [66]. Arab
descent patients had a predominance of oligoarticular
subtype [66]. Patients of Arab descent had the highest
predominance of systemic disease subtype, almost twice
higher than Asian descent patients 23.5% vs. 12%. In
contrast, African descent patients had an equal distribu-
tion of oligoarticular and RF negative polyarticular dis-
ease and had the highest RF positive polyarticular
disease prevalence amongst all ethnicities at 16.1% [66].
RF negative polyarticular JIA was the second most
identified subtype in Africa and Middle East. The RF
negative subtypes were reported to be the predominate
subtype in Kuwait, [13, 14] Oman, [11, 33] and Saudi
Arabia [35]. One study from Morocco reported predom-
inance of RF-positive polyarthritis [40]. And only one
study from Egypt identified undifferentiated subtype
(40%) to be predominant [46]. Globally, RF negative
polyarticular JIA was recognized to be most prevalent in
North America and least in Southeast Asia [22]. Region-
ally, RF negative polyarticular JIA was identified at 22.6%
from the PRAG study, [28] and 22.4% from the EPOCA
study [22].
One study from Morocco (45.5%) [40] and one study
from Egypt (25.4%) [49] reported a higher prevalence of
RF positive polyarthritis as compared to RF negative
subtype. The exact cause for a higher frequency of RF
positive polyarthritis is unknown but can be attributed
to genetics and selection bias. Among the studies that
tested and reported rheumatoid factor results, Jordan re-
ported the lowest RF positivity at 3.8% [37]. Regionally,
RF positive polyarthritis was identified from the PRAG
study at 6.8% [28] and 5% from the EPOCA study [22].
In the Canadian multiethnic cohort study, patients with
African descent had the highest prevalence of RF posi-
tive polyarthritis and a lower uveitis rate [66]. This

























Systemic arthritis 42 (5.0) 57 (6.9) 204 (8.5) 167 (8.2) 22 (4.2) 149 (17.6) 204 (16.9) 125 (33.0)
Oligoarticular 340 (40.2) 317 (38.1) 1360 (56.7) 848 (41.5) 185 (35.4) 261 (30.7) 457 (37.8) 41 (10.8)
RF-negative
polyarthritis
223 (26.4) 198 (23.8) 480 (20.0) 539 (26.4) 165 (31.5) 217 (25.6) 271 (22.4) 48 (12.7)
RF-positive
polyarthritis
30 (3.6) 22 (2.6) 31 (1.3) 91 (4.5) 22 (4.2) 95 (11.2) 61 (5.0) 30 (7.9)
Psoriatic arthritis 35 (4.1) 40 (4.8) 88 (3.7) 54 (2.6) 37 (7.1) 13 (1.5) 37 (3.1) 5 (1.3)
Enthesitis related
arthritis
87 (10.3) 125 (15.0) 130 (5.4) 254 (12.4) 56 (10.7) 83 (9.8) 111 (9.2) 113 (29.8)
Undifferentiated
arthritis
88 (10.4) 73 (8.8) 107 (4.5) 91 (4.5) 36 (6.9) 31 (3.7) 68 (5.6) 17 (4.5)
Data are number (%)
ILAR = International League of Associations for Rheumatology
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observation has been made in multiple studies describ-
ing the African population [67, 68]. The subtype fre-
quencies of various geographic regions are presented in
Table 6.
Notably, most of the Saudi Arabia studies reported
systemic JIA subtype to be the most frequent [32, 34–
36, 39] and in only one study from Turkey (26.3%) [51].
Saudi Arabia was the only country that reported sys-
temic subtype as the most frequent from multiple stud-
ies [32, 35, 36, 39]. Higher incidence of systemic JIA was
associated with large familial clusters in the country, es-
pecially in the southern region [32, 69]. Familial JIA sug-
gest an autosomal recessive mode of inheritance with
specific mutations in genetic markers like LACC1 [70,
71]. It has been observed that familial systemic JIA pa-
tients were younger at the onset of disease and diag-
nosed earlier than sporadic JIA cases and had a
predominance of refractory disease with progressive dis-
ease course [32]. These findings were attributed to a
high consanguinity marriage, and potential referral bias
(severe cases presentation) [32, 35, 69]. Systemic JIA was
identified at 16.9% from Africa and Middle East region
in the EPOCA study [22] and identified at higher preva-
lence of 24.5% was observed in the PRAG study [28]. A
lower frequency of systemic JIA subtype was observed in
studies from Turkey [50] and South Africa [57] at 3.9%
and 4.4%, respectively.
Enthesitis related arthritis (ERA) subtype was most fre-
quent from three retrospective chart studies from
Turkey, reported at 34.5% from Istanbul, [50] 32.9%
from Denizli region [41] and 32.8% from the Adana re-
gion [61]. A third study from Istanbul identified ERA as
the second most frequent subtype in 21.7% of the cases
analyzed [51]. The lowest frequency of ERA subtype was
reported from Saudi Arabia (1.2%), [34] United Arab
Emirates (1.5%) [52]. It was observed that several studies
from Iran, [59] Oman, [33] Saudi Arabia, [32, 36, 39]
and Egypt [49, 53] reported no ERA cases in their co-
hort. However, two studies from South Africa (23% and
15.4%) [57, 60] reported higher prevalence of ERA sub-
types than others. The trend for the high frequency of
ERA in South Africa was attributed to the high popula-
tion of people of Asian and European descent in some
regions in South Africa [60].
EPOCA study identified ERA subtype in 9.2% of all
cases in Africa and Middle East region, and PRAG study
at 5.6% of all JIA cases [22, 28]. This finding of higher
predominance of boys in one Turkish study was attrib-
uted by high frequency of ERA in Turkey which is more
frequent in males than in females [41].
ERA subtype was identified at 9.2% and 5.6% from the
EPOCA and PRAG studies, respectively [28]. And glo-
bally, ERA has been highest among southeast Asia and
lowest in Southern Europe [22, 66]. The possible reason
for the lower prevalence of ERA in the Arab and African
populations is unknown but can explained by higher in-
cidence of ERA in post-pubertal male, which may be re-
ferred to adult rheumatologists and not counted as JIA
in pediatric rheumatology literature. Arab ERA patients
showed greater articular damage with significant limita-
tion [28]. Intra-country differences were observed in the
frequency of JIA subtypes in Turkey [61]. Denizli and
Istanbul regions reported ERA as the most common
subtype, [41, 61] while oligoarticular was the most
prevalent subtype in Adana, [62] Diyarbakir, [58] and
from a regional multi-center registry study in Turkey
[44]. The heterogenic nature of the Turkish population,
cultural, socioeconomic, food habits, and mixed ethnici-
ties have resulted in region wide variations [50, 61].
Psoriatic arthritis and undifferentiated arthritis were
the least reported JIA subtype across all the studies from
the region, and this observation is aligned with other re-
gions globally [22].
In various studies conducted across the globe, an over-
all female predominance for JIA was observed [8, 22].
Our literature review also supports that JIA is more
likely to occur in girls than in boys in the region [22].
However, notable differences in the ratios exist across
the different countries in the region. We observed a
higher female to male ratio in most studies conducted in
individual countries from Africa and Middle East [11–
13, 29–39, 42, 44, 45, 48, 52, 53, 55, 57–59, 61, 63]. Eight
studies reported number of male cases to be higher in
comparison to female cases. These included five studies
from Turkey (female to male ratio - 0.94:1 [41], 0.6:1
[15], 0.87:1 [51], 0.92:1 [62], and 0.77:1 [56],) two from
Egypt (female to male ratio - 0.9:1 [49] and 0.88:1 [46]),
and one from Morocco (female to male ratio - 0.83:1
[40]). Notably, studies from Lebanon, Kuwait, South Af-
rica, and Tanzania cohorts showed near equal gender
distribution [14, 43, 47, 60]. In various studies conducted
across the globe, an overall female predominance for JIA
was observed [8, 22]. A similar trend was observed in
most studies conducted in individual countries from Af-
rica and Middle East [11–13, 29–39, 42, 44, 45, 48, 52,
53, 55, 57–59, 61, 63]. The multinational EPOCA [22]
and PRAG [28] studies identified a predominance of
girls in the identified JIA cases. The female to male ratio
ranged from 1.6:1 [22] to 2:1 [28].
It is noticeable that there is female predominance in
many autoimmune diseases, however, the referral bias
and study methodologies, case ascertainment and geog-
raphy can contribute to the variance in gender ratios
[72–74]. Male predominance has been reported in some
studies that maybe explained by unequal school and
medical care provided to male and female children, es-
pecially in the rural areas [14, 21]. Globally two studies
identified higher prevalence of disease in girls than in
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boys 19.4 (18.3-20.6) per 100,000 and 11.9 (10.2-11.9)
per 100,000 [95% CI], respectively [8]. The higher pre-
dominance of JIA in boys has also been linked to high
frequency of ERA by one Turkish study [41].
ANA positivity was identified in 30.9% of cases from
the PRAG study [28]. From the local studies, the lowest
frequency of ANA was reported in a study from Egypt
(0%) [46] and highest from Morocco (76%) [40]. Other
studies that reported relatively higher ANA positivity
rates included 48.5% from Egypt [12], 44% from Turkey
[61] and 36.5% from Saudi Arabia [34]. Notably, several
local studies reported no ANA-positive patients in all its
cohort. Our findings from this review conclude that a
wide heterogeneity in ANA positivity among JIA studies
can be attributed to genetics, different methods of ANA
ascertainment and the unavoidable referral bias.
The human leukocyte antigen (HLA) - B27 was identi-
fied regionally in 5.3% cases by the PRAG study [28].
The majority of studies did not test for HLA-B27 in all
patients, and some opted to test HLA-B27 in suspected
ERA cases only. Among those studies, an Egyptian study
reported 66% positivity, a South African study reported
23% positivity, and a Turkish study reported 63.3% posi-
tivity in the confirmed ERA cases [12, 44, 60]. One study
from Turkey tested HLA-B27 in all ERA phenotype
cases and in males over six years of age and reported
26% positivity rate [41]. One study analyzed HLA-B27 in
all its patients [39]. One of the studies that analyzed
HLA-B27, all JIA subtypes reported 21.1% positivity in
overall cohort. However, all HLA-B27 positive patients
were of ERA subtype [61].
Our findings from this review observed that uveitis
and ANA positivity rates seem to be low for Africa and
Middle East region. In individual countries, uveitis’
prevalence ranged from 1% from Iran [59] to 19.7% from
Egypt [12]. Uveitis was identified in 8.3% of the PRAG
study cases [28] and 5.9% from the EPOCA study [22].
The EPOCA study observed the lowest prevalence of
uveitis in Africa and Middle East as compared to other
regions [22] (Refer to Table 7). PRAG study reported a
higher rate of uveitis i.e., 8.3% [28]. Two studies from
Oman reported zero cases of uveitis from their cohorts
[11, 33]. We identified one outlier study from Egypt, that
reported 19.7% of the cohort with evidence of uveitis
predominantly in the oligoarticular subtype. Coinci-
dently, the same study reported high ANA positivity in
its cohort in 48.5% cases and a high frequency of both
combined ANA positivity and uveitis in oligoarticular
subtype 62.3% [12]. Saurenman et al, 2007 also reported
a lower relative risk of developing uveitis in Arab and
Asian descent patients than European or native North
American ethnic groups [66]. Similar findings have been
observed in the African population [67, 68].
Across many studies conducted on JIA subtypes
worldwide, a wide heterogeneity in the pattern of dis-
ease, age of onset, sex, and phenotypes has been ob-
served [22, 66] owing to factors such as immunogenetic,
socioeconomic status, environment, and diagnostic cri-
teria [21, 61]. The wide diversity of study design and
diagnostic criteria used adds to the challenge of forming
a reliable picture of the demographics in the region. Fur-
ther, there is a lack of uniformity with regards to the
type and definition of biomarkers tested (RF, HLA-B27,
ANA) and the subtype they are tested in [21, 66]. In
some countries, there could be a recruitment bias in
studies for patients >10 years of age, as they consult an
adult rheumatologist [40]. Factors that may influence
the heterogeneity in JIA subtype frequency within the
region included: diverse socioeconomic, cultural, nutri-
tional habits and genetics. Migration between the differ-
ent parts of the region results in mixed ethnicities and
different genetic constructs and could significantly con-
tributor to this heterogeneity [66].
The readers should note that the observations should
be approached with caution owing to the heterogenicity
of the studies pooled. Most of the studies included in
this manuscript for reviewing the demographics are
single-centered, retrospective study with notable selec-
tion biases. Some of the studies included were limited by
their sample size.
Region-specific unmet needs
Several factors can contribute to the delays in proper diag-
nosis and management of JIA which vary region wise. The
challenges include access to rheumatology services, access
to proper diagnosis and therapies, and lack of awareness
of rheumatic musculoskeletal disorders at the policymaker
and public level and general pediatricians [23, 24]. Limited
access to rheumatologists has been identified as a global
challenge, which has also been reported in Africa than in
Middle East region. The ratio of practicing rheumatolo-
gists ranged 0.3-0.89 rheumatologists per 100,000 in the
Gulf and reported lower in Africa 0-0.01 per 100,000 com-
pared to 1.78 per 100,000 in USA [23]. This challenge is
further amplified for pediatric patients due to the even
greater limitation of pediatric rheumatologists' access and
pediatric rheumatology training [24, 75]. The disparities in
regulatory approval timelines, health care system settings,
economies, and the level of a financial burden on patients
may vary considerably across Africa and Middle East.
International guidelines recommend initiating treat-
ment soon after diagnosis and setting remission of dis-
ease as the optimal treatment target [76–78]. Those with
a longer duration of un-or undertreated disease may
only achieve minimal improvement in disease activity.
There are limited local and regional guidelines, Inter-
national guidelines exist but are not always applicable in
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the region because of the high costs of new therapies
and the constraints of regular follow-up. Algeria has de-
veloped their national JIA treatment guideline and is
published in French [79]. In Egypt, registries have been
set up to advance the cause and local guideline is
underdevelopment.
A recommendation for management of JIA in less
resourced countries has also been developed in a global ef-
fort which included experts from South Africa, Kenya and
Zambia [80]. At the same time, other countries follow
established international guidelines such as ACR, EULAR
[35, 76–78]. There are regional collaborations being estab-
lished throughout the region between countries under
PRAG group which is a part of the Arab League of Associ-
ations for Rheumatology (ArLAR). The aim of these col-
laborations is to develop the field of pediatric
rheumatology in the region, provide a network of research
collaboration to address the unmet needs for patients, de-
velop a consensus on JIA evidence generation and local
treatment guidelines. As stated by an ongoing Pediatric
Task Force Global Musculoskeletal Health there is a real
need to improve research and outcomes for musculoskel-
etal disorders [81]. There are initiatives like Pediatric Soci-
ety of the African League Against Rheumatism (PAFLAR)
and Global Task Force for Musculoskeletal Health and
Pediatric Rheumatology European Society (PReS), who
have recognized the need and are working towards reach-
ing out to children with rheumatic diseases who do not
have access to proper care [82].
Conclusion
The region of Africa and Middle East is very diverse in
terms of socioeconomic conditions, environmental factors,
ethnicities, and healthcare infrastructures. There is a pau-
city of the latest and adequate data on JIA on its epidemi-
ology. In the absence of databases or registries to track
disease progression, JIA data for Africa and Middle East
are generally derived from hospital-based studies,
providing limited accounts of epidemiology. Prospective,
population-based studies are preferable in descriptive epi-
demiology, compared to studies using secondary data that
depend upon hospital or public health registry systems.
However, such studies are expensive, time-consuming,
and consequently rare, especially in lower-income coun-
tries. Hence, a comprehensive review was planned to crit-
ically analyze the available data from the region. The
prevalence rates of the region are relatively lower com-
pared to the global estimates. The reasons for the wide
range reported from the region include differences in
study designs, methodologies, reach to healthcare facil-
ities, and non-uniform study methodologies. From the
demographic data gathered, it was concluded that the oli-
goarticular subtype was the predominant one over another
subtype in Africa and Middle East. It was also noted that
the incidence of uveitis and ANA positivity in Africa and
Middle East region was lower as compared to the inci-
dence from other parts of the world. The region has an
evident unmet need for awareness, delayed diagnosis, lack
of an adequate number of rheumatologists, no published
local or regional guidelines, and economic disparities.
These lacunae need to be addressed to effectively manage
JIA in the region.
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Girls 593 (70.2%) 538 (64.7%) 1763 (73.5%) 1303 (63.7%) 374 (71.5%) 550 (64.8%) 745 (61.6%) 164 (43.3%)
Boys 252 (29.8%) 294 (35.3%) 637 (26.5%) 741 (36.3%) 149 (28.5%) 299 (35.2%) 463 (38.3%) 215 (56.7%)
Age at onset (years) 4.7 (2.2 – 9.4) 6.4 (2.7 –
10.4)


























2.8 (1.2 – 5.4) 3.9 (1.9 –
6.7)
Uveitis 161 (19.1%) 94 (11.3%) 450 (18.8%) 183 (9.0%) 59 (11.3%) 54 (6.4%) 71 (5.9%) 19 (5.0%)
Data are n(%) or median (IQR)
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